BioPharmSignal logoBioPharmSignal

Biotech News

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney (PROK)ProKidneyEarnings

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology

Related news

PROKProKidney2026-03-18 20:00 EST

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

PROKProKidney2025-11-10 21:15 EST

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

View all latest news

ProKidney

Regenerative Kidney Medicine ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation. Rilparencel Rilparencel, also known as REACT, is a...

Recent company news

PROKProKidney2026-08-10 20:05 EST

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

PROKProKidney2026-06-02 12:00 EST

ProKidney Appoints Kenneth Locke as Chief Technical Officer

PROKProKidney2026-05-15 15:45 EST

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

PROKProKidney2026-03-25 20:01 EST

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

PROKProKidney2026-03-18 20:00 EST

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

Stock data

Close
1.61 USD
Market cap
389.88M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States